Cetrorelix Research: What 807 Studies Show (2026) | RetatrutideCompare

Cetrorelix — 807 studies indexed on PubMed. Competitive GnRH receptor antagonist. Immediate suppression of LH surge without the agonist flare. Half-life: ~30 hours (3 mg dose). FDA status: FDA-approved (2000).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Cetrorelix?

There are approximately 807 studies indexed on PubMed that mention Cetrorelix (Cetrotide), based on a search last updated 2026-06-18.

Is Cetrorelix FDA-approved?

FDA status: FDA-approved (2000).

How does Cetrorelix work?

Competitive GnRH receptor antagonist. Immediate suppression of LH surge without the agonist flare.

Reference facts

Also known as: Cetrotide
Category: GnRH & Reproductive
Mechanism of action: Competitive GnRH receptor antagonist. Immediate suppression of LH surge without the agonist flare.
Targets: GnRH receptor (antagonist)
Indications under research or approved: Prevention of premature LH surge during controlled ovarian stimulation in IVF
Regulatory status (reference entry): FDA-approved (2000)
Half-life: ~30 hours (3 mg dose)
Sequence notes: Decapeptide GnRH antagonist Ac-D-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2.
Molecular weight (Da): 1431
Originator / sponsor: Merck Serono / EMD Serono
First reported: 1991

Primary References

Cetrotide FDA label

Explore research articles about Cetrorelix

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.